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Abstract
During SARS-CoV-1 and Middle East Respiratory Distress Syndrome (MERS) 
outbreaks it was observed a particularly elevated incidence of cardiovascular disease 
among patients. With COVID-19, this correlation becomes evident again. However, 
the cardiovascular impacts by COVID-19 pandemic are not yet well established 
although publications about its potential deleterious effects are constant. Thus, 
aimed to carry a systematic review of the literature with meta-analysis, the follow-
ing question was used as a guide: what practical contributions does the scientific 
literature produced in the period of 2019-2020 has to offer about the impact of the 
COVID-19 on cardiovascular system? A systematic review of the literature using 
the Virtual Health Library (VHL) and PubMed with the following descriptors: 
#1 “cardiovascular disease” [MeSH] AND #2 “COVID-19” [keyword], as well as 
their equivalents in the Portuguese and Spanish language, during the period from 
December 2019 to March 2020 was performed. One hundred articles were found 
in Pubmed and twenty-seven were selected. In VHL there are 59 articles and four 
were selected totaling thirty-one papers. The findings were then divided into 
three subcategories: Etiology, Physiopathology and Risk factors of SARS-CoV-2 in 
Cardiovascular System; Clinical presentation, laboratory markers and imagenologi-
cal aspects of SARS-CoV-2 in cardiovascular system; and Anti-Hypertensive Drugs, 
Cardiovascular System and SARS-CoV-2. When it comes to the cardiovascular 
system, these issues are aggravated and urge as a joint commitment from research-
ers, medical and governmental organizations to carry out more robust studies with 
bold methodologies aimed at mapping prognostic factors and assertive therapeutic 
approaches in the management of cardiovascular complications of COVID- 19.
Keywords: cardiovascular disease, coronavirus infections, clinical medicine, 
systematic review
1. Introduction
According to the WHO, there has been a recent increase in the burden of 
cardiovascular disease (CVD), especially in low and middle-income countries [1]. 
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It is estimated that 17.7 million people died from CVD in 2015, representing 31% 
of all deaths globally [2]. In 2020, CVDs are the number 1 cause of death globally, 
taking an estimated of 17.9 million lives each year [3, 4].
COVID-19 again brought the need to discussion an extremely relevant topic that 
was of concern during the SARS-CoV-1 (SARS - 2002) and Middle East Respiratory 
Distress Syndrome (MERS - 2013) epidemics, the increase incidence of cardiovas-
cular disease among patients [5]. Studies show that patients with comorbidities, 
such as hypertension, heart failure, diabetes [6] and elderly people [7] are, among 
other factors, risk factor for severe illness by SARS-CoV-2. Also, COVID-19 is 
caused by the binding of the viral surface spike protein to the human angiotensin-
converting enzyme 2 (ACE2) receptor following activation of the spike protein by 
transmembrane protease serine 2 (TMPRSS2) [8]. Thus, the cardiovascular impacts 
by COVID-19 pandemic are not yet well established although publications about its 
potential deleterious effects are constant.
Aimed to carry a systematic review of the literature with meta-analysis, the fol-
lowing question was used as a guide: what practical contributions does the scien-
tific literature produced in the period of 2019-2020 has to offer about the impact of 
the COVID-19 on cardiovascular system? This review highlights that in a pandemic 
period, cardiovascular pathologies are risk factors from a worsening result. The 
pandemic prevention and control measures can also be used as a way to prevent 
cardiovascular diseases on the population, since fewer people exposed to the virus 
means less cardiovascular risk.
2. Methods
2.1 Literature review
A qualitative systematic review with meta-analysis of the literature using 
the Virtual Health Library (VHL), which hosts recognized databases – LILACS 
(Literatura Latino-americana e do Caribe em Ciências da Saúde), MEDLINE, 
SciELO (Scientific Electronic Library Online), and PubMed was performed. 
Initially, the following descriptors were used: #1 “cardiovascular disease” [MeSH] 
AND #2 “COVID-19” [keyword], as well as their equivalents in the Portuguese and 
Spanish language.
2.2 Eligibility criteria
The period reported in the literature ranged from December 2019 to March 
2020 since the pandemic started in this period. Compilation of the data was 
performed in April 2020. Manuscript selection occurred primarily through the 
analysis of titles and abstracts. Article analysis followed the eligibility criteria: 
(1) At least a combination of the terms described in the search strategy were 
present in the title or words that refer to the theme; (2) Articles written in 
English, Portuguese or Spanish; (3) Articles addressing cardiovascular impact 
of COVID-19 pandemic; (4) Papers repeated in more than one database were 
computed only once; (5) Original papers with the full text available through 
in a virtual library created by the Brazilian Ministry of Health where con-
tent is restricted to authorized users - the CAPES (Coordination of Personal 
Improvement of Higher Level) Periodicals Portal. Thesis, dissertations, and 
monographs were excluded. Some articles were excluded because they generally 







































Author (Year) Journal Sample (Study type) Main Findings
Guo et al. [9] JAMA Cardiol 187 patients with confirmed 
COVID-19 at the Seventh Hospital of 
Wuhan City, China (cross sectional 
retrospective observational study).
During hospitalization, 66 (35.3%) patients had underlying CVD including hypertension, coronary 
heart disease, and cardiomyopathy, and 52 (27.8%) exhibited myocardial injury as indicated by elevated 
TnT levels. Patients with elevated TnT levels had more frequent malignant arrhythmias, and the use of 
glucocorticoid therapy (37 [71.2%] vs. 69 [51.1%]) and mechanical ventilation (41 [59.6%] vs. 14 [10.4%]) 
were higher compared with patients with normal TnT levels.
Clerkin et al. [8] Circulation (Integrative Review) COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which 
invades cells through the angiotensin converting enzyme 2 (ACE2) receptor. Among those with COVID-
19, there is a higher prevalence of cardiovascular disease and more than 7% of patients suffer myocardial 
injury from the infection (22% of the critically ill).
Bansal [10] Diabetes Metab 
Syndr
(Narrative Review) Acute cardiac injury, defined as significant elevation of cardiac troponins, is the most commonly reported 
cardiac abnormality in COVID-19.
Cheng et al. [11] Curr Cardiol Rep (Integrative Review) Emerging epidemiological evidence suggest cardiovascular risk factors are associated with increased 
disease severity and mortality in COVID-19 patients. Patients with a more severe form of COVID-19 are 
also more likely to develop cardiac complications such as myocardial injury and arrhythmia.
Li et al. [12] Infection Dis 
Poverty
31 normal human tissues 
(Experimental study)
ACE2 expression levels were the highest in the small intestine, testis, kidneys, heart, thyroid, and adipose 
tissue, and were the lowest in the blood, spleen, bone marrow, brain, blood vessels, and muscle. ACE2 
showed medium expression levels in the lungs, colon, liver, bladder, and adrenal gland
Han et al. [13] J Cardiovasc Magn 
Reson
(Integrative Review) First, continued urgent and semi-urgent care for the patients who have no known active COVID-19 should 
be provided in a safe manner for both patients and staff. Second, when necessary, CMR on patients with 
confirmed or suspected active COVID-19 should focus on the specific clinical question with an emphasis 
on myocardial function and tissue characterization while optimizing patient and staff safety.
Slawiński and 
Lewicka [14]
Kardiol Pol (Integrative Review) Among comorbidities in patients with COVID-19, cardiovascular disease is most commonly found. And in 
the most common symptoms of COVID-19 dyspnea is responsible by18.6%-59%.
Berre et al. [15] Diagn Interv 
Imaging.
71-year-old man with COVID-19 
pneumonia (Case Report)
A case report about concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-
19 pneumonia
Vignera et al. 
[16]
Int J Mol Sci. (Short Communication) Data on the experimental animal have shown that 17B-estradiol increases the expression and activity of 
ACE2 in both adipose tissue and kidney. Spontaneously hypertensive male mice have a higher myocardial 
ACE2 expression than females and its levels decrease after orchiectomy
Zhu et al. [17] Curr Cardiol Rep (Integrative Review) The literature reports association between history of cardiac disease and worsened outcome during 
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60-year-old man with COVID-19 
pneumonia (Case Report)




Eur J Epidemiol. (Short Communication) SARS-CoV-2 infection produces enzymatic shedding that inactivates ACE2 and prevents conversion of 
Ang-II. This effect could in part explain the cardiovascular and respiratory manifestations of COVID-19.
Gao et al. [20] Respir Res 102 patients with severe COVID-19 
(cross sectional observational study)
N terminal pro B type natriuretic peptide (NT-proBNP) might be an independent risk factor for 




Curr Cardiol Rep (Integrative Review) Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), 
possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar 
epithelial cells.
Wang and  
Xu [22]
Cells 17,520 testicular cells (Experimental 
Study)
ACE2 is predominantly enriched in spermatogonia and Leydig and Sertoli cells. Gene Set Enrichment 
Analysis (GSEA) indicates that Gene Ontology (GO) categories associated with viral reproduction and 
transmission are highly enriched in ACE2-positive spermatogonia, while male gamete generation related 
terms are downregulated.
Rizzo et al. [23] Basic Res Cardiol (Short Communication) We might be able to target Notch also to fight heart and lung disease caused directly by SARS-CoV-2 
infection and by the cytokine storm in response to the virus.
Laccarino  
et al. [5]
High Blood Press 
Cardiovasc Prev
(Short Communication) In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the 
promotion and antagonism of the disease. The available literature, indeed, presents contrasting results.
Schiffrin  
et al. [24]
Am J Hypertens (Short Communication) There is as yet no evidence that hypertension is related to outcomes of COVID-19, or that ACE inhibitor or 
ARB use is harmful, or for that matter beneficial, during the COVID-19 pandemic.
Tan and 
Aboulhousn [25]
Int J Cardiol (Integrative Review) COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, 
cardiac injury, and death.




(Integrative Review) Patients with COVID-19 infection have elevated natriuretic peptides, significance of which is uncertain 
and Cardiac troponin I levels are significantly increased in patients with severe SARS- CoV-2 infection.
Gackowski et al. 
[27]
Kardiol Pol (Integrative Review) Transesophageal echocardiography is considered an aerosol-generating procedure and should be 
performed only as a lifesaving procedure. Personnel should use appropriate personal protection equipment 
in the immediate vicinity of the patients in accordance with the relevant guidelines.
Guo et al. [28] J Am Heart 
Associat
(Integrative Review) ACE2 plays a protective role in both cardiovascular diseases and acute lung injury. For uninfected patients, 
we tend to believe it is unnecessary to discontinue ACEIs/ARBs given the lack of evidence to support 
the hypothesis that ACEIs/ARBs might lead to an increased risk of SARS-CoV-2 infection. For infected 
patients, although higher ACE2 expression might be associated with higher viral loads, ACEIs/ARBs should 
not be discontinued assertively because they can block the RAS and protect patients from the potential 







































Author (Year) Journal Sample (Study type) Main Findings
Sommerstein  
et al. [29]
J Am Heart 
Associât
(Integrative Review) Cardiovascular diseases and/or their therapy, by affecting ACE2 levels, may play a pivotal role with regard 
to infectivity and outcome of COVID-19. Whether treatment or disease induced upregulation of ACE2 
influences the course of COVID-19 urgently needs to be determined.
Meng et al. [7] Emerg Microbes 
Infect.
51 patients with hypertension 
and COVID-19 (cross sectional 
retrospective study)
Patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level 
of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in 
peripheral blood and decreased the peak viral load compared to other antihypertensive drugs.
Vanduganathan  
et al. [30]
N Engl J Med (Integrative Review) Insufficient data are available to determine whether these observations readily translate to humans, and no 
studies have evaluated the effects of RAAS inhibitors in Covid-19
Chen et al. [31] Cardiovasc Res Human heart tissues were obtained 
from abandon donors in Center of 
Cardiovascular Treatment in China 
(Experimental Study)
The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing 
microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 
expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have 
higher risk of heart attack and critically ill condition.
Fang et al. [6] Lancet Respir Med (Short Communication) patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs, are 
at higher risk for severe COVID-19 infection
Chen et al. [32] Herz (Short Communication) The condition of some patients with severe SARS-CoV-2 infection patients might deteriorate rapidly with 
acute respiratory distress syndrome and septic shock, which is eventually followed by multiple organ 
failure and fulminant myocarditis
Hulot et al. [33] Arch Cardiovasc 
Dis
(Short Communication) COVID-19 can be caused palpitations and chest tightness, myocardial damage with an increase in high-
sensitivity cardiac troponin I.
South et al. [34] Am J Physiol Heart 
Circ Physiol
(Short Communication) In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with 
RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are 
at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and 
the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic 
respiratory disease.
Abassi et al. [35] Am J Physiol Heart 
Circ Physiol
(Short Communication) In patients infected with SARS-CoV-2, ACE2 may transform to a Trojan horse. Its binding with ACE2 
neutralizes the advantageous cardiac effects of this enzyme, especially in patients with heart failure.
CVD – Cardiovascular Disease; TnT – Troponin T; ACE2 - angiotensin converting enzyme 2; CMR – Magnetic Ressonance; NT-proBNP - N terminal pro B type natriuretic peptide; Ang-II- Angiotensin II; 
ARB - angiotensin-receptor blockers; RAAS - renin-angiotensin-aldosterone system; CD – Cluster of Differentiation.
Table 1. 
Main Findings.
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To ensure trustworthiness of the findings, data collection was performed, 
individually, by two researchers with divergences being solved by a third senior 
researcher.
Each sample article was thoroughly read and the information was inserted in a 
spreadsheet (Table 1), including the author, publishing year and main study find-
ings. According to the PRISMA protocol (http://www.prisma- statement.org/).
2.3 Ethical issues
Since this is a systematic review, Resolution 510/16 of the Brazilian National 
Health Council (CNS) ensures the dispensation of submission to a Human Beings 
Research Ethics Committee.
3. Result
According to the research strategy, 101 articles were found in Pubmed and 27 
were selected. In VHL, 59 articles were found and four were selected. After the 
eligibility criteria was applied (Figure 1), the results were input in Table 1.
The findings were then divided into three subcategories: Etiology, 
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Clinical presentation, laboratory markers and imagenological aspects of SARS-
CoV-2 in cardiovascular system; and Anti-Hypertensive Drugs, Cardiovascular 
System and SARS-CoV-2.
4. Discussion
4.1  Etiology, physiopathology and risk factors of SARS-CoV-2 in cardiovascular 
system
SARS-CoV-2 is caused by a novel enveloped beta coronavirus that belongs to 
the Coronaviridae family, a group of positive strand RNA viruses causing human 
respiratory infections. Named after the crown shaped outer coat seen on the 
electron-microscopy, it was first discovered in the 1960s, receiving great attention 
during the 2003 SARS coronavirus (SARS-CoV) outbreak [11]. Seven species of 
these beta-coronaviruses are known to cause human infections, with four mainly 
causing mild flulike symptoms and the remaining three resulting in potentially fatal 
illnesses (SARS, MERS and the ongoing COVID-19) [10].
The transmission of COVID-19 occurs mainly through droplets route. However, 
there are theories that this can occur by fecal-oral route or/and by airborne. The 
average incubation time is less than six days (5.1 days), less than three percent of 
patients (2,5%) develop disease before the third day (2.2 days) after acquiring the 
virus while the rest (97,5%) develop symptoms 11.5 days after the onset of infec-
tion [27].
Although respiratory tract is the primary target for SARS-CoV-2, cardiovascu-
lar system (CVS) may get involved in several different ways [10] as destabilized 
coronary plaque [9], hypoxemia, systemic inflammation and enhanced myocardial 
oxygen demand, a direct cardiovascular injury, likely develops, initiated by binding 
of SARS-CoV-2 to angiotensin-converting enzyme 2 (ACE2) (Figures 2 and 3). This 
receptor is widely expressed in lungs, kidney [5] - renal tubules [26], brain, gut 
[34], gastrointestinal epithelium, Leydig cells in testis [22, 26], but also in the heart, 
where it is localized to macrophages, vascular endothelium, smooth muscle and 
myocytes [33].
Experimental study shows that the immune activity levels (innate immune 
response - NK cells and acquired immune response - B cells, CD8+ T cells and inter-
feron response) in countless human tissues with large number of ACE2 receptors 
are statistical significant (P < 0.05, 0.27 ≤ r ≤ 0.78). In the research, the following 
tissues obtained higher levels of CD8+ T cell - brain, blood vessels, skin and diges-
tive system (pancreas, colon, stomach and esophagus) [3]. On the other hand, 
high levels of beta 17ß-estradiol have been shown to be important for increasing 
the number of ACE2 receptors in kidney and adipose tissues in laboratory stud-
ies. Interestingly, spontaneously hypertensive male mice, after orchiectomy, have 
higher levels of ACE2 than females [16].
In fact, the virus shares the ACE2 as the host cellular receptor for virus spike (S) 
protein according to structural analysis [31, 35] following activation by transmem-
brane protease serine 2 (TMPRSS2) [34]. The virus produces enzymatic shedding 
that inactivates ACE2 and prevents conversion of Ang-II [19]. Besides that, virus 
infection causes damage to pericytes and endothelial dysfunction, especially due 
to damage to capillary endothelial cells. The increased expression of ACE2 proteins 
and mRNAs in patients infected by the virus and with basic heart failure disease 
may have higher risk of critically ill condition and/or heart attack [31] (Figure 2).
Laboratory studies have suggested that other intracellular signaling pathways 
such as Notch could also explain the cytokine storm that ultimately induces heart 
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and lung disease caused by SARS-CoV-2 direct damage to tissues [23]. Besides that, 
other theory is that the “cytokine storm” - term for increasing various interleukins 
and chemokines as TNF-α, IFN-γ, GCSF, MCP-1, MIP-1-α, IL-10, IL-6 and IL-2 
contributes to cardiac injury. These situations are analogous to cardiotoxicity in the 
setting of CAR- T cell (chimeric antigen receptor - T cell) therapy. In this paper, left 
Figure 2. 
The role of ACE2 in COVID-19. The spike protein of SARS-CoV-2 binds ACE2 on a cellular membrane, 
which triggers 1) endocytosis of the virus and subsequent sequestration of ACE2 or 2) cleavage of the viral spike 
protein via an enzyme TMPRSS2 leading to the entry of viral contents into the cytoplasm [adapted]. Source: 
Cheng et al. [11].
Figure 3. 
Renin–angiotensin system inhibition (RAS) by Angiotensin converting enzyme/Ang-II receptor blockers 
(ACEI/ARBs) and SARS-CoV-2 binding to ACE2 receptors [adapted]. Source: Gonzallez-Jamarilo et al. [19].
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ventricular systolic dysfunction, cardiac injury and cardiovascular events (troponin 
elevation) post-CAR-T have been demonstrated [17].
Therefore, the exact mechanism of cardiac involvement in COVID-19 remains 
under investigation but it seems the SARS-CoV-2 can (a) cause cardiac injury 
indirectly due to a probable overwhelming immune inflammatory response and 
cytokine storm; (b) cause invasion of cardiomyocytes and direct damage via this 
process; (c) cause Severe hypoxia from acute respiratory damage caused by the 
virus may result in oxidative stress and myocardial injury from increased myo-
cardial oxygen demand in the presence of severe hypoxia due to acute lung injury 
(ARDS) [25].
Cardiovascular disease patients are at particularly high risk for mortality from 
SARS-CoV-2 due to their frailty and susceptibility for a myocardial involvement 
[36], perhaps due to the virus’s affinity for ACE2 (Figure 3) mainly due to the 
interaction with the renin-angiotensin-aldosterone system (RAAS).
RAAS has an important role in regulating blood pressure and electrolyte bal-
ance. This system compromises two pathways: ACE2/Ang (1–7)/Mas receptor and 
ACE/Ang II/AT1R. In physiological situations, these two metabolic pathways func-
tion harmoniously, maintaining the normal function [7] (Figure 3). Hence, RAAS 
is widely implicated in Diabetes mellitus (DM), hypertension, heart failure [21] and 
Coronary heart disease [29].
Patients with COVID-19 are often diagnosed with coronary artery disease 
(2.5–8%), diabetes (7.3%–18.8%), hypertension (15%–30.4%) and other cardiovas-
cular disease (4%–14.6%). In addition, of the patients who had been admitted to 
the intensive care unit (ICU), those with cardiovascular diseases compared to those 
who had not had a worse prognosis [9, 14, 24].
Another fact to be considered is that COVID-19 is more aggressive in elderly 
patients. The literature tells us that the elderly and male have more ACE2 receptors 
than the general population [29]. About that, Li et al. [3] refer that, when studying 
the expression of ACE2 receptors in various tissues of the body and its correlation 
with immunogenicity, in the thyroid, lungs, adrenal gland, liver, and kidneys, ACE2 
expression levels showed significant positive correlations with CD8+ T cell enrich-
ment levels solely in males.
Finally, patients with chronic kidney and those who have received renal 
transplant - and have a higher cardiovascular risk - are at increased risk of 
COVID-19 infection and severity. Moreover, there are frequent renal function 
abnormalities and increased incidence of acute kidney injury in patients with 
COVID- 19 [26].
4.2  Clinical presentation, laboratory markers and imagenological aspects of 
SARS-CoV-2 in cardiovascular system
There appears to be two clinical stages to the disease. The first stage is the rep-
licative stage, when SARS-CoV-2 is replicating over the course of several days and 
the patient presents with relatively mild symptoms [25] such as fever, cough, and 
myalgia or fatigue; less common symptoms were sputum production, headache, 
hemoptysis, and diarrhea [32]. The adaptive immunity stage is the second stage. 
The body produces antibodies against the virus and, as there is viral clearance, the 
antibody titers will return to baseline values and an infection solves. This creates 
an “Immune memory”. However, a minority of patients becomes critically ill and 
have high mortality rates [25]. It is important to remember that some symptoms 
in patients with COVID-19 pneumonia suggest cardiovascular diseases. Fatigue, 
dyspnea, cough is typical in COVID-19, but these symptoms may also result from 
exacerbation of chronic heart failure [14].
Fighting the COVID-19 Pandemic
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Chinese study shows large number of patients (81%) with mild symptoms of 
COVID-19 between (no pneumonia and mild pneumonia). These patients with more 
aggressive symptoms, 14% has more severe clinical conditions (lung infiltrates >50% 
within 24 to 48 hours, partial pressure of arterial oxygen to fraction of inspired 
oxygen ratio < 300, blood oxygen saturation ≤ 93%, respiratory rate ≥ 30/min and 
dyspnea) and 5% critical medical conditions (septic shock, respiratory failure and/or 
multiple organ dysfunction or failure) [37]. Others publishing and anecdotal reports 
indicate manifestations of arrhythmia [28], cardiac arrest, acute heart failure [23] 
and theoretically fulminant myocarditis [17, 32].
COVID-19 virus enters cells through the angiotensin converting enzyme II 
(ACE2) receptor, resulting in down-regulation of ACE2 receptor function. This 
leads to an increase of angiotensin II activity, activation of the renin-angio-
tensin-aldosterone system (RAAS) following a decrease in ACE2, an increase 
in vasoactive, proliferative, and profibrotic Ang-II leads to cardiopulmonary 
damage through hemodynamic changes such as pulmonary hypertension and 
interstitial edema followed by respiratory failure in the most severe cases 
(Figure 3) [19].
In laboratory markers, definitive diagnosis of SARS-CoV-2 Infection is based 
primarily on nucleic acid amplification tests, such as real-time reverse transcrip-
tase–polymerase chain reaction (rRT-PCR) [27].
The laboratory alterations found in COVID-19 include in descending level elevated 
concentrations of serum creatine kinase (7%–13.7%), total bilirubin (10.5–18%), 
transaminases (21–28%), D-dimer concentration (36%–46.4%), lactate dehydroge-
nase (41–76%), C-reactive protein (60.7–93%), thrombocytopenia (17%–36.2%) and 
lymphopenia (35%–82.1%). It is important to note that the first three have been rarely 
reported [14].
Interesting to note that elevated D-dimer values are common in COVID-19 
patients, even in the absence of thrombophlebitis and acute pulmonary embolism 
and it seems to correlate with acute pulmonary embolism [18], arterial thrombosis, 
acute respiratory distress syndrome and death [15]; elevated cardiac troponin I 
(cTnI) levels [32] and N terminal pro B type natriuretic peptide (NT-proBNP), 
with the cut-off value of 88.64 pg./mL [20] are correlate with cardiovascular injury, 
hospitalization and death. Including, plasma TnT levels in patients with COVID-19 
correlated significantly with both plasma high-sensitivity C-reactive protein levels, 
NT-proBNP elevation and malignant arrhythmias [20].
According to Clerkin et al. [9] the rise in elevated high sensitivity cTnI tracks 
with other inflammatory biomarkers (D-dimer, ferritin, interleukin-6 (IL-6), 
lactate dehydrogenase and elevated creatinine kinase, raising the possibility that it 
may reflect on cytokine storm or secondary hemophagocytic lymphohistiocytosis 
more than isolated myocardial injury.
Transthoracic echocardiography is routinely recommended in patients with 
complicated COVID-19 due to the high prevalence of heart failure or/and myo-
carditis. This measure is useful to differentiate dyspnea of pulmonary origin from 
dyspnea of cardiac origin and monitor the sequelae of ARDS. Another useful use 
of echocardiography in the medical practice of ICU is monitoring treatments 
such as extracorporeal membrane oxygenation and fluid management in shock. 
Ultrasound evaluation of the lung may be a sensitive marker of fluid accumula-
tion in the interstitial space and it useful for show the most common changes 
present in lungs how consolidation, B-line artifacts (the earliest signs in the 
disease course) and pleural line abnormalities like >1 mm, loss of continuity and 
irregularity [27].
Cardiovascular Magnetic Resonance (CMR) is useful in mapping of the extent of 
myocardial injuries, impact on ventricular function and differentiating a etiologies 
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(ischemic from non-ischemic). It stills helps in differentiating the between myocar-
ditis and other acute myocardial injury that can elevate myocardial enzymes  
(eg. Troponin) and alter electrocardiographic (ECG) patterns [13].
4.3 Anti-hypertensive drugs, cardiovascular system and SARS-CoV-2
Even at the beginning of the pandemic, a publication suggested that due to hyper 
expression of ACE2 receptors in DM and hypertension, patients with said condi-
tion would be more likely to develop severe manifestations of COVID-19 [6] which 
was not confirmed with subsequent studies [21, 24, 30, 34]. At the same time, 
there was a theory that anti-hypertensive drugs could cause more severe cases of 
COVID-19, however it has been refuted. Meng et al. [27] showed that ACE inhibi-
tors (ACEi) or angiotensin receptor-1 blockers (ARB) therapy increased CD3 and 
CD8 T cell counts in peripheral blood and decreased the peak viral load compared 
to other antihypertensive drugs and Rico-Mesa et al. [24] suggest that the effects of 
these drugs were positive, including ACE2 receptor blockade, disabling viral entry 
into the heart and lungs, and an overall decrease in inflammation secondary to 
ACEI/ARB.
Moreover, Societies of Hypertension affirms that in hypertensive patients with 
COVID-19 or at risk of COVID-19 infection, ACEi and ARBs treatment should be 
maintained according to the recommendations contained in the 2018 ESC/ESH 
guidelines [5], because blood pressure control remains an important consideration 
in order to reduce disease burden, even if it has no effect on susceptibility to the 
SARS-CoV-2 viral infection [24].
5. Final considerations
Cardiovascular diseases (CVD) are one of the most important causes of morbid-
ity and mortality in the world being a great challenge for clinicians and research-
ers in the context of COVID-19. The pathophysiological explanation suggests an 
intimate correlation between SARS-CoV-2 protein S and ACE2 receptors, which 
the virus takes advantage of to increase its ability to penetrate host cells. The 
aggression of the cardiovascular system can be divided into three hypotheses - 
direct damage of the cardiomyocyte by the virus; hypoxemia due to lung injury 
or coronary events; or exacerbated immune response. When it comes to patients 
with COVID-19, the coexistence of previous cardiovascular diseases or risk factors 
such as hypertension, diabetes, coronary heart disease and heart failure, in addi-
tion to biochemical markers such as high troponin and pro-BNP seem to increase 
mortality.
Thus, when it comes to the cardiovascular system, these issues are aggravated 
and urge as a joint commitment from researchers, medical and governmental 
organizations to carry out more robust studies with bold methodologies aimed at 
mapping prognostic factors and assertive therapeutic approaches in the manage-
ment of cardiovascular complications of COVID- 19.
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